SRNE - Sorrento Therapeutics' Slow-But-Steady Approach to COVID-19
Sorrento Therapeutics (NASDAQ: SRNE) has taken a broad approach to developing tests, treatments, and vaccines for COVID-19. In the process, the biotech certainly hasn't broken any biotech speed records and trails the leaders in each of the three categories.
Nevertheless, in this video from Motley Fool Live recorded on Nov. 12, Henry Ji, chairman, president, and CEO of Sorrento, says the broad approach hasn't slowed down development. Ji thinks the company's neutralizing antibodies are potentially more active than the frontrunners, which could help the biotech catch up and compete.
For further details see:
Sorrento Therapeutics' Slow-But-Steady Approach to COVID-19